Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Assets (2020 - 2025)

Keros Therapeutics' Return on Assets history spans 6 years, with the latest figure at 0.16% for Q4 2025.

  • For Q4 2025, Return on Assets rose 47.0% year-over-year to 0.16%; the TTM value through Dec 2025 reached 0.16%, up 47.0%, while the annual FY2025 figure was 0.18%, 56.0% up from the prior year.
  • Return on Assets reached 0.16% in Q4 2025 per KROS's latest filing, up from 0.09% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.16% in Q4 2025 to a low of 0.49% in Q4 2023.
  • Average Return on Assets over 5 years is 0.25%, with a median of 0.33% recorded in 2022.
  • Peak YoY movement for Return on Assets: fell -13bps in 2022, then soared 47bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.24% in 2021, then tumbled by -55bps to 0.37% in 2022, then crashed by -30bps to 0.49% in 2023, then surged by 36bps to 0.31% in 2024, then skyrocketed by 151bps to 0.16% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Return on Assets are 0.16% (Q4 2025), 0.09% (Q3 2025), and 0.02% (Q2 2025).